# A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

> **NCT01345201** · PHASE1 · COMPLETED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** OMP-18R5

## Key facts

- **NCT ID:** NCT01345201
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01345201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01345201, "A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01345201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*